<>
Laboratory research from the University of Cambridge indicates that common sweeteners, particularly when paired with medications or food additives, can inhibit the growth of bacteria essential to a healthy gut microbiome. While these findings highlight potential risks for metabolic and immune health, the study was conducted in controlled laboratory settings, and further clinical research is required to determine the impact on human health.
Laboratory Findings on Sweeteners and Gut Bacteria
Researchers at the University of Cambridge’s Medical Research Council (MRC) Toxicology Unit have identified that many sweeteners are not biologically inert. According to the study published in Molecular Systems Biology, approximately three-quarters of the 39 sweeteners tested inhibited the growth of at least one bacterial species.
The study utilized 25 distinct bacterial species to monitor how these microorganisms reacted to various natural and artificial sweeteners. By observing the rate at which these bacterial cultures multiplied, the team found that several common additives could significantly slow or stop the growth of beneficial gut bacteria, which are vital for digestive function and blood sugar regulation.
Unexpected Chemical Interactions
The study revealed that sweeteners rarely act in isolation within the human body. Because people often consume sweeteners alongside caffeine, flavorings, or medications, the researchers tested these combinations to simulate real-world consumption.
The team documented over 100 cases where the influence of a sweetener on gut bacteria changed in the presence of another compound. In 34 of these instances, the combined effect on bacterial growth was stronger than the effect of the sweetener alone.
The Duloxetine and Isosteviol Connection
The most notable interaction observed involved the combination of isosteviol—a sweetener used in the food and beverage industry—and duloxetine, an antidepressant. When combined, these two compounds significantly suppressed the growth of Roseburia intestinalis and Parabacteroides merdae.
These specific bacterial species are linked to metabolic health and immune function. The researchers noted that because duloxetine is a widely prescribed medication, with over 4.2 million prescriptions issued in the U.S. in 2023, these interactions warrant further investigation.
Implications for Microbial Diversity
To better simulate the complexity of the human gut, the researchers created a synthetic microbial community containing all 25 bacterial species. Exposure to the combination of isosteviol and duloxetine led to a reduction in overall microbial diversity.
A diverse microbiome is generally associated with a resilient digestive system. The study found that this combination not only reduced diversity but also shifted the internal balance of the community, allowing some species to flourish while others declined. These changes were further linked in laboratory models to increased toxicity toward host cells and the disruption of immune response pathways.
The Need for Human Clinical Trials
While these findings challenge the assumption that sweeteners are metabolically neutral, the researchers emphasize that they do not constitute proof of harm in humans. The study relied on laboratory and cell-based models, which cannot fully replicate the human digestive environment.
Factors such as the absorption of compounds, chemical changes during digestion, individual genetics, and existing microbiome composition could significantly alter these results. Professor Kiran Patil and Dr. Sonja Blasche, the study’s authors, stress that future research is necessary to determine if these interactions occur in people and what levels of consumption might lead to measurable health outcomes. The research was supported by the UK Medical Research Council and the European Union’s Horizon 2020 program.
Related reading